Table 1

Indications for DES Use

1. “On-label” or FDA-approved use
 CYPHER Sirolimus-eluting Coronary Stent (5)
 For improving coronary luminal diameter in patients with symptomatic ischemic disease due to discrete de novo lesions in native coronary arteries
  •   • ≤30 mm in length

  •   • 2.5–3.5 mm in diameter

  •   • 50%–99% stenosis

 TAXUS Express 2 Paclitaxel-Eluting Coronary Stent System (6)
 For improving luminal diameter for the treatment of de novo lesions in native coronary arteries
  •   • ≤28 mm in length

  •   • 2.5–3.75 mm in diameter

  •   • 50%–99% stenosis

2. “Off-label” or beyond FDA-approved use
 Lesion subsets
  •   • Multivessel disease

  •   • Left main disease

  •   • Bifurcation lesions

  •   • Chronic total occlusions (CTO)

  •   • In-stent restenosis (ISR)

  •   • Small vessels (<2.5 mm in diameter) or large vessels (>3.75 mm in diameter)

  •   • Long lesions requiring multiple or overlapping stents

  •   • Saphenous vein grafts (SVG)

  •   • Thrombus containing lesions (acute MI)

 High-risk patient subsets
  •   • Diabetics

  •   • Renal dysfunction

DES = drug-eluting stent; FDA = Food and Drug Administration; MI = myocardial infarction.